Pituitary/growth disorders


Observational data confirm that children born small for gestational age achieve the best growth outcomes if they start treatment with recombinant human growth hormone as young as possible.
A multigene sequencing panel has successfully identified one or more gene variants in up to one in six children with idiopathic short stature, researchers report in Endocrine Connections.
Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.

In depth

Professor Martin Savage discusses the roles of clinical, endocrinological and genetic testing in the diagnosis and care of children with idiopathic short stature.
REGISTRATION NOW OPEN! This is the 9th IMAGE programme, which focuses on transgender management, bone health, and the genetics and treatment of growth disorders.
Why is the growth plate the most important organ for childhood growth: how can it be investigated for clinical diagnosis?
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
Martin Savage
Programme Director

Sign up for eAlerts

Be the first to hear about new resources and content by signing up to receive our eAlerts.

Please provide your details:

Follow us
This programme is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.
medwireNews is an independent clinical news service provided by Springer Healthcare Limited. © 2023 Springer Healthcare is part of the Springer Nature Group